Sevoflurane vs. propofol for general Anesthesia in patients with acute ischemic stroke treated with endoVascular treatmEnt (SAVE trial)

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-523709-13-00

Enrollment

330

Registered

2026-04-07

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute ischemic stroke

Brief summary

The primary outcome of the study will be the final infarct volume (FIV), assessed by Fluid-Attenuated Inversion Recovery (FLAIR) sequence on magnetic resonance imaging (MRI) follow-up at 72 hours post-treatment ± 24 hours.

Interventions

DRUGSevoflurano Baxter 100% líquido para inhalación del vapor EFG

DRUGPropofol Fresenius 20 mg/ml emulsión inyectable y para perfusión EFG

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The primary outcome of the study will be the final infarct volume (FIV), assessed by Fluid-Attenuated Inversion Recovery (FLAIR) sequence on magnetic resonance imaging (MRI) follow-up at 72 hours post-treatment ± 24 hours.	—

Outcome results

None listed

Source: EU CTIS · Data processed: Apr 8, 2026